74733-25-8

Basic information

• Product Name: Methyl 3-fluoro-4-forMylbenzoate
• Synonyms: Methyl 3-fluoro-4-forMylbenzoate;4-Methyl 3-fluoro-4-formylbenzoate
• CAS NO: 74733-25-8
• Molecular Formula: C₉H₇FO₃
• Molecular Weight: 182.1484832
• Mol File: 74733-25-8.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 290.9±30.0 °C(Predicted)
• Appearance: /
• Density: 1.271±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Methyl 3-fluoro-4-forMylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-fluoro-4-forMylbenzoate(74733-25-8)
• EPA Substance Registry System: Methyl 3-fluoro-4-forMylbenzoate(74733-25-8)

Safety Data

• Hazardous Substances Data: 74733-25-8(Hazardous Substances Data)

Usage

General Description

Methyl 3-fluoro-4-formylbenzoate is a specialized chemical compound known for its unique properties. Its systematic name is methyl 3-fluoro-4-carboxybenzaldehyde, and its molecular formula is C9H7FO3. The compound belongs to the group of chemicals called Benzoic acid and derivatives, which are organic compounds containing a benzene ring which is conjugated to a carboxylic acid. It is a volatile liquid or solid compound (depending on temperature), has a characteristic smell, and can be synthesized in a laboratory. It's important to note that while details about usage are not widely available, like all chemicals, it must be handled with care to prevent harmful exposure.

Upstream product

• 1134777-51-7 4-dibromomethyl-3-fluorobenzoic acid methyl ester 
• 350-28-7 3-fluoro-4-methyl-benzoic acid 
• 87808-48-8 methyl 3-fluoro-4-methylbenzoate 
• 128577-47-9 methyl 4-(bromomethyl)-3-fluorobenzoate 
• 74733-29-2 2-methyl-3-hydroxybenzoic acid methyl ester 
• 193290-80-1 3-fluoro-4-formylbenzoic acid 
• 74-88-4 methyl iodide 
• 777074-51-8 4-(dibromomethyl)-3-fluorobenzoic acid 
• 849758-12-9 methyl 4-bromo-3-fluorobenzoate 
• 141-53-7 sodium formate 
• 153556-42-4 4-bromo-3-fluorobenzoic acid 

Downstream Products

• 314241-04-8 2-fluoro-terephthalic acid 4-methyl ester 
• 364082-38-2 methyl 4-[trans-5-[[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]thio]-1,3-dioxan-2-yl]-3-fluorobenzoate 
• 1134776-52-5 (R,S)-3-fluoro-4-(1-hydroxyethyl)benzoic acid methyl ester 
• 193290-80-1 3-fluoro-4-formylbenzoic acid 
• 1402345-21-4 3-fluoro-4-[3-oxo-3-(2-phenylamino-pyridin-3-yl)-propyl]-benzoic acid methyl ester 
• 1402345-22-5 3-fluoro-4-{3-[2-(methoxyoxalyl-phenyl-amino)-pyridin-3-yl]-3-oxo-propyl}-benzoic acid methyl ester 
• 1402345-23-6 3-(4-carboxy-2-fluoro-benzyl)-4-oxo-1-phenyl-1,4-dihydro-[1,8]naphthyridine-2-carboxylic acid methyl ester 
• 944044-83-1 2-fluoro-4-(2-hydroxypropan-2-yl)benzaldehyde 

Relevant articles and documents

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase

Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent BTK inhibitors is limited to oncology indications based on their suboptimal kinase selectivity. We describe the discovery and preclinical profile of LOU064 (remibrutinib, 25), a potent, highly selective covalent BTK inhibitor. LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases. It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis. LOU064 is currently being tested in phase 2 clinical studies for chronic spontaneous urticaria and Sjoegren's syndrome.

PIPERIDINYL- SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS

Compounds of Formula I: and pharmaceutically acceptable salts thereof, in which X1, X2, R3, R4, R5, Rx, R7, R9, R10 and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EPl receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EPl receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EPl receptor as well as to pharmaceutical compositions comprising them.